Our findings emphasize the importance of integrating molecular and clinical assessments in PD and suggest that interventions aimed at enhancing SIRT1/Nrf2-mediated neuroprotection or reducing NLRP3-mediated inflammation may improve both symptom burden and quality of life. This evidence concerns the gene NLRP3 and Parkinson disease.